A detailed history of Erste Asset Management Gmb H transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 26,900 shares of DNLI stock, worth $627,039. This represents 0.01% of its overall portfolio holdings.

Number of Shares
26,900
Holding current value
$627,039
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $563,824 - $835,245
26,900 New
26,900 $792 Million
Q4 2023

Nov 26, 2024

SELL
$16.2 - $23.18 $4.99 Million - $7.13 Million
-307,769 Reduced 91.96%
26,900 $590 Million
Q3 2023

Nov 26, 2024

BUY
$20.63 - $30.17 $6.35 Million - $9.29 Million
307,769 Added 1144.12%
334,669 $684 Million
Q2 2022

Nov 26, 2024

BUY
$20.88 - $35.19 $286,056 - $482,102
13,700 Added 103.79%
26,900 $780 Million
Q1 2022

Nov 22, 2024

SELL
$29.0 - $47.27 $107,300 - $174,899
-3,700 Reduced 12.09%
26,900 $872 Million
Q4 2021

Nov 22, 2024

BUY
$42.59 - $55.02 $157,583 - $203,574
3,700 Added 13.75%
30,600 $1.35 Billion
Q4 2020

Nov 22, 2024

SELL
$36.89 - $93.56 $4.12 Million - $10.4 Million
-111,600 Reduced 78.48%
30,600 $2.57 Billion
Q3 2020

Nov 22, 2024

BUY
$23.13 - $38.84 $2.67 Million - $4.48 Million
115,300 Added 428.62%
142,200 $5.11 Billion
Q4 2019

Nov 22, 2024

BUY
$14.4 - $19.99 $1.66 Million - $2.3 Million
115,300 Added 428.62%
142,200 $2.5 Billion
Q2 2019

Nov 22, 2024

BUY
$18.5 - $28.14 $1.85 Million - $2.81 Million
100,000 Added 236.97%
142,200 $2.94 Billion
Q1 2019

Nov 22, 2024

BUY
$17.99 - $24.65 $275,247 - $377,145
15,300 Added 56.88%
42,200 $944 Million
Q4 2018

Nov 26, 2024

SELL
$13.88 - $21.75 $190,156 - $297,975
-13,700 Reduced 50.93%
13,200 $257 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.13B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.